Latest Imatinib Stories
Although significant progress has been made in treating chronic myeloid leukemia, the disease cannot yet be eliminated in all patients, and that challenge must be addressed.
It's estimated that nearly one-third of the world's population—more than two billion people—are infected with Mycobacterium tuberculosis.
SUNNYVALE, Calif., Aug. 9, 2011 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced the release of an updated XpertÂ® BCR-ABL Monitor test, now reporting results to the International Scale.
Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib.
EAST HANOVER, N.J., June 5, 2011 /PRNewswire/ -- Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking GleevecÂ® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment.
FRANKLIN LAKES, N.J. and PORTLAND, Ore., June 2, 2011 /PRNewswire/ -- Medco Health Solutions, Inc. (NYSE: MHS) and MolecularMD Corp. today announce the launch of a personalized medicine program for chronic myeloid leukemia (CML) patients.